Co-Diagnostics, Inc. Raises $3.8 Million through Direct Stock Offering to Accelerate Growth in Molecular Diagnostics

Co-Diagnostics, Inc. Completes $3.8 Million Direct Stock Offering

On September 18, 2025, Co-Diagnostics, Inc. (Nasdaq: CODX) officially announced the closing of its $3.8 million direct offering of common stock. This significant financial move marks a critical step for the Utah-based molecular diagnostics company, known for its proprietary platform that develops advanced diagnostic tests.

Overview of the Offering

The company executed a registered direct offering aligned with Nasdaq regulations, allowing it to sell 9,619,000 shares of common stock at a price of $0.40 per share. The total amount raised, before deducting agent fees and other expenses, amounts to approximately $3.8 million. The funds generated will be utilized primarily for working capital and various corporate initiatives aimed at bolstering the company's market positioning and technological advancements.

Maxim Group LLC played a pivotal role as the sole placement agent in facilitating this offering, showcasing confidence in Co-Diagnostics’ business model and future potential.

The direct offering was conducted under a previously established shelf registration statement, which had been declared effective by the U.S. Securities and Exchange Commission (SEC) back in April 2023. This approach allows companies like Co-Diagnostics to access capital efficiently without the lengthy process typically associated with public offerings.

Company Profile and Future Direction

Co-Diagnostics is a notable player in the molecular diagnostics landscape. The company develops and markets innovative diagnostics technologies primarily focused on the detection and analysis of nucleic acid molecules, such as DNA and RNA. Their proprietary technologies are instrumental in conducting tests that are vital for identifying genetic markers, particularly for applications beyond infectious diseases.

The funds from this latest offering will be strategically invested to expand their product range and enhance their Co-Dx PCR platform, which is designed for at-home testing and point-of-care diagnostics. As the demand for molecular diagnostics continues to rise, driven by heightened awareness of global health and disease prevention, Co-Diagnostics is positioning itself for accelerated growth and expansion in both domestic and international markets.

Industry Context

The molecular diagnostics sector has seen remarkable growth over the past few years, particularly in response to the global pandemic that underscored the need for rapid and accurate testing solutions. As such, companies like Co-Diagnostics are well-poised to capitalize on ongoing advancements in technology and increasing healthcare spending.

In addition to its immediate use of proceeds, the company plans to explore collaborative partnerships and potential market expansions. The ability to respond quickly to changing healthcare needs and advancements in diagnostic science will play a crucial role in Co-Diagnostics’s strategy moving forward.

Conclusion

As Co-Diagnostics continues to leverage its innovative technologies and robust market strategy, the completion of this $3.8 million direct offering serves not just as a financial boost, but as a critical lever for its ambitions in the ever-evolving landscape of molecular diagnostics. Investors and stakeholders are keen to monitor the outcomes of this funding as the company seeks to redefine the future of diagnostic testing.

For further information regarding the offering and the company's progress, potential investors can access detailed documents filed with the SEC or reach out to Maxim Group LLC for personalized inquiries.